VIEW MORE
Non-canonical proteins are unconventional protein products that are not part of the known protein-coding genome repertoire. They arise from unexpected...
Non-canonical proteins as candidate targets for cancer immunotherapy
VIEW MORE
Recently published in the Journal of Medical Genetics* results of a case-control study spearheaded by VHIO’s Judith Balmaña show that...
Cancer-related secondary/incidental exome results in patients with rare, non-oncological malignancies: the clinical impact and psychological implications
VIEW MORE
Intrahepatic cholangiocarcinoma (ICC) is a rare cancer with a poor prognosis. Surgery is the main curative option but up to...
Efficacy and safety of next-generation FGFR inhibitor futibatinib in patients with metastatic cholangiocarcinoma

Latest News

Non-canonical proteins are unconventional protein products that are not part of the known protein-coding genome repertoire. They arise from unexpected...

Non-canonical proteins as candidate targets for cancer immunotherapy
Non-canonical proteins are unconventional protein products that are not part of the known protein-coding genome repertoire. They arise from unexpected...

Recently published in the Journal of Medical Genetics* results of a case-control study spearheaded by VHIO’s Judith Balmaña show that...

Cancer-related secondary/incidental exome results in patients with rare, non-oncological malignancies: the clinical impact and psychological implications
Recently published in the Journal of Medical Genetics* results of a case-control study spearheaded by VHIO’s Judith Balmaña show that...

Intrahepatic cholangiocarcinoma (ICC) is a rare cancer with a poor prognosis. Surgery is the main curative option but up to...

Efficacy and safety of next-generation FGFR inhibitor futibatinib in patients with metastatic cholangiocarcinoma
Intrahepatic cholangiocarcinoma (ICC) is a rare cancer with a poor prognosis. Surgery is the main curative option but up to...

Now published by the ESMO Daily Reporter (formerly by the ESMO Perspectives online magazine), the latest edition of  On Target – Gathering...

ESMO Daily Reporter On target column: VHIO’s Elena Garralda on cellular immunotherapy against solid tumors
Now published by the ESMO Daily Reporter (formerly by the ESMO Perspectives online magazine), the latest edition of  On Target – Gathering...

Research Programs

PRECLINICAL & TRANSLATIONAL RESEARCH
Cellular Plasticity and Cancer Group

Our group focuses on the interplay between cellular plasticity, stem cells and cancer. Cellular plasticity is recognized today as a critical feature of cancer cells that enables them to transit between different cellular states, including reversible transitions.

Cellular Plasticity and Cancer Group
PRECLINICAL & TRANSLATIONAL RESEARCH
Growth Factors Group

We focus our research on mechanisms of resistance to targeted therapies and most importantly, how to overcome it by showing that breast cancers resistant to T-DM1, an antibody-drug conjugate ADC)- can be efficiently treated with the second generation ADC SYD985 (Nadal-Serrano et al.).

Growth Factors Group
CORE TECHNOLOGIES
Cancer Genomics Group

VHIO’s Cancer Genomics Group serves as a Core Technology laboratory. We are also dedicated to translational research as well as the development of novel genomic tests.

Cancer Genomics Group

PRINCIPAL RESEARCHERS

JUDIT_BALMAÑA
Judith Balmaña
Hereditary Cancer Genetics Group

We focus on the clinical development of PARP inhibitors (PARPi) in early gBRCA1/2 breast cancer, and novel combinations in the…

Cristina-Saura00007
Cristina Saura
Breast Cancer & Melanoma Group

The main area of expertise of the Breast Cancer Group is clinical research focused on drug development and associated translational…

Rodrigo_Dientsmann
Rodrigo Dientsmann
Oncology Data Science (ODysSey) Group

VHIO’s ODysSey Group promotes translational research in precision oncology by integrating cancer molecular profiling data with clinical outcomes of oncology…

TERESA
Teresa Macarulla
Gastrointestinal and Endocrine Tumors Group

Our group continues to play an essential role in developing molecular therapies against GI malignancies. We make important contributions to…

Events

Friday 24 March 23 - 12:00 PM scientific-seminars Seminars Jakob Kather | Artificial intelligence-based biomarkers in precision oncology
Friday 24 March 23 - 02:50 PM Seminars 4ª SESIÓN DE ACTUALIZACIÓN EN TERAPIAS DIRIGIDAS EN PACIENTES ALK+ Y EGFR
Thursday 30 March 23 - 11:00 AM Patients Mindfulness workshop. Learning to live and enjoy the present
Thursday 20 April 23 - 11:00 AM Patients Practical physical exercise workshop. How can we reconnect with our body through the practice of physical exercise?